Dateline City:
KENILWORTH, N.J.
Further Analyses on the Long-Term Safety and Efficacy of VYTORIN from the IMPROVE-IT Study Presented at the European Society of Cardiology (ESC) Meeting
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD in the United States and Canada, today
announced results from new analyses from the IMPROVE-IT study.
IMPROVE-IT presents us with the opportunity to look at cardiovascular
outcomes data for patients treated with the combination of simvastatin
and ezetimibe (VYTORIN) and allows us to look at the important aspect of
long-term safety and efficacy under controlled conditions, said Dr.
Michael A. Blazing, Duke Department of Medicine.
Language:
English
Contact:
For MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more